Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.65 +2.8%	$1.73	$1.41 ▼ $5.01	$9.59M	1.29	37,881 shs	41,193 shs
BFRI Biofrontera	$0.96 +10.0%	$0.85	$0.54 ▼ $2.22	$9.77M	0.5	237,077 shs	67,827 shs
DWTX Dogwood Therapeutics	$4.95 +0.2%	$4.82	$1.62 ▼ $29.28	$9.45M	1.8	1.71 million shs	6,030 shs
SPRC SciSparc	$4.63 +9.5%	$6.34	$4.00 ▼ $37.59	$2.45M	0.88	161,530 shs	431,454 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.91%	-5.33%	-23.08%	-4.19%	-58.55%
BFRI Biofrontera	+1.47%	-7.56%	-0.89%	+39.57%	-26.20%
DWTX Dogwood Therapeutics	+1.65%	+0.22%	+5.33%	-5.73%	+493,999,900.00%
SPRC SciSparc	+1.44%	-13.85%	-48.35%	-34.49%	-50.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.6218 of 5 stars	3.5	5.0	0.0	0.0	3.2	0.8	1.3
BFRI Biofrontera	2.7932 of 5 stars	3.5	5.0	0.0	0.0	1.9	0.0	0.6
DWTX Dogwood Therapeutics	1.861 of 5 stars	3.5	0.0	0.0	0.0	2.2	0.0	0.6
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	842.25% Upside
BFRI Biofrontera	3.00	Buy	$2.75	185.36% Upside
DWTX Dogwood Therapeutics	3.00	Buy	$10.00	102.02% Upside
SPRC SciSparc	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPRC, DWTX, BFRI, and APRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.39	N/A	N/A	$2.30 per share	0.72
BFRI Biofrontera	$37.32M	0.26	N/A	N/A	($0.46) per share	-2.10
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	($9.48) per share	N/A
SPRC SciSparc	$1.31M	1.87	N/A	N/A	$18.13 per share	0.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.32	N/A	N/A	N/A	-1,645.01%	-78.90%	-62.67%	11/6/2025 (Estimated)
BFRI Biofrontera	-$17.76M	-$2.26	N/A	N/A	N/A	-42.34%	-1,104.09%	-82.28%	N/A
DWTX Dogwood Therapeutics	-$12.35M	-$18.78	N/A	N/A	N/A	N/A	N/A	-27.41%	11/6/2025 (Estimated)
SPRC SciSparc	-$6.28M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SPRC, DWTX, BFRI, and APRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	BFRI Biofrontera	-$0.45	-$0.57	-$0.12	-$0.57	$8.30 million	$9.03 million
8/13/2025	Q2 2025	DWTX Dogwood Therapeutics	-$1.26	-$1.99	-$0.73	-$1.99	N/A	N/A
8/12/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	-$0.53	+$0.24	-$0.53	N/A	$0.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
DWTX Dogwood Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.34	5.34
BFRI Biofrontera	8.99	0.96	0.75
DWTX Dogwood Therapeutics	N/A	7.80	7.80
SPRC SciSparc	N/A	5.36	5.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
BFRI Biofrontera	10.08%
DWTX Dogwood Therapeutics	9.05%
SPRC SciSparc	25.06%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
BFRI Biofrontera	4.80%
DWTX Dogwood Therapeutics	3.90%
SPRC SciSparc	1.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.83 million	5.03 million	No Data
BFRI Biofrontera	70	10.14 million	9.65 million	No Data
DWTX Dogwood Therapeutics	5	1.91 million	1.84 million	N/A
SPRC SciSparc	4	530,000	527,000	Not Optionable

SPRC, DWTX, BFRI, and APRE Headlines

Recent News About These Companies

SciSparc Announces Patent Filing and Merger Updates

August 8, 2025 | theglobeandmail.com

SciSparc and Clearmind Publish Patent for Novel Obesity Therapy

August 8, 2025 | tipranks.com

SciSparc Ltd. and Clearmind Medicine Inc. Collaborate to Launch International Patent Application for Innovative Therapy Targeting Metabolic Syndrome and Obesity

August 7, 2025 | quiverquant.comQ

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

August 7, 2025 | globenewswire.com

SciSparc Ltd: SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 31, 2025 | finanznachrichten.de

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

July 30, 2025 | globenewswire.com

Clearmind Medicine files international patent application under PCT

July 30, 2025 | msn.com

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

July 30, 2025 | globenewswire.com

SciSparc Ltd. Regains Nasdaq Compliance

July 22, 2025 | tipranks.com

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

July 22, 2025 | globenewswire.com

SciSparc Announces 1-for-21 Reverse Share Split - Morningstar

June 26, 2025 | morningstar.comM

SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum

June 25, 2025 | msn.com

SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share Split

June 25, 2025 | finanznachrichten.de

SciSparc Ltd. Announces One-for-Twenty One Reverse Share Split Effective July 3, 2025

June 24, 2025 | quiverquant.comQ

SciSparc Announces 1-for-21 Reverse Share Split

June 24, 2025 | globenewswire.com

SciSparc secures Japanese patent for pain relief combo

May 28, 2025 | investing.com

SciSparc Unveils Japanese Patent for Novel Pain Relief Combination

May 27, 2025 | tipranks.com

SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA

May 27, 2025 | quiverquant.comQ

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025 | globenewswire.com

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.

May 13, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC, DWTX, BFRI, and APRE Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.64 +0.05 (+2.81%)

Closing price 03:59 PM Eastern

Extended Trading

$1.63 -0.02 (-0.91%)

As of 06:30 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Biofrontera NASDAQ:BFRI

$0.96 +0.09 (+10.05%)

Closing price 03:54 PM Eastern

Extended Trading

$0.95 -0.01 (-1.21%)

As of 05:59 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Dogwood Therapeutics NASDAQ:DWTX

$4.95 +0.01 (+0.20%)

Closing price 03:57 PM Eastern

Extended Trading

$4.97 +0.02 (+0.32%)

As of 05:36 PM Eastern

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

SciSparc NASDAQ:SPRC

$4.63 +0.40 (+9.46%)

Closing price 03:58 PM Eastern

Extended Trading

$4.58 -0.05 (-1.19%)

As of 06:48 PM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time